ABT

$105.46-1.73 (-1.61%)

Market ClosedAs of Mar 20, 8:04 PM UTC

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide.

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$105.46
Potential Downside
17.6%
Whystock Fair Value$86.91
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Devices

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medica...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$183.26B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
28.35
Beta
Defensive asset. Lower volatility than the S&P 500.
0.74
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Elite ROE. Management converts capital into profit efficiently.
26.82%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.18

Recent News

Insider Monkey
Mar 21, 2026

Is Abbott Laboratories (ABT) A Good Stock To Buy Now?

Is ABT a good stock to buy? We came across a bullish thesis on Abbott Laboratories on Compounding Dividends’s Substack by TJ Terwilliger. In this article, we will summarize the bulls’ thesis on ABT. Abbott Laboratories’s share was trading at $109.56 as of March 6th. ABT’s trailing and forward P/E were 29.45 and 19.30, respectively according to Yahoo […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
TipRanks
Mar 21, 2026

Transformational Opportunities: UBS Suggests 2 Longevity Stocks to Buy as the $8T Aging Boom Accelerates

For years, the conversation around getting older has focused on individuals – retirement, lifestyle, healthcare. But a bigger story has been quietly unfolding in the background. The U.S. population itself is aging, and that shift is starting to ripple far beyond personal milestones. The Chief Investment Office at UBS views this trend as a foundation for long-term portfolio positioning. It frames “longevity” as a structural theme – a growing, aging population with evolving needs, particularly in

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MT Newswires
Mar 20, 2026

Sector Update: Health Care Stocks Retreat Late Afternoon

Health care stocks declined late Friday afternoon, with the NYSE Health Care Index and the State Str

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MedTech Dive
Mar 20, 2026

Abbott to close $21B Exact Sciences acquisition Monday

Abbott said it has received all regulatory clearances necessary to buy the cancer screening firm.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Motley Fool
Mar 19, 2026

1 Magnificent Dividend Stock Down 22% That's a Screaming Buy Right Now

Don't give up on this leading dividend payer yet.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.